Accesso libero

Correlation of laminin subunit alpha 3 expression in pancreatic ductal adenocarcinoma with tumor liver metastasis and survival

Yueyi Xing
Yueyi Xing
, 
Xue Jing
Xue Jing
, 
Gong Qing
Gong Qing
 e 
Yueping Jiang
Yueping Jiang
   | 07 mar 2024
Radiology and Oncology's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Article Category: Research Article
Pubblicato online: 07 mar 2024
Pagine: 234 - 242
Ricevuto: 30 ott 2023
Accettato: 14 gen 2024
DOI: https://doi.org/10.2478/raon-2024-0020
Parole chiave
© 2024 Yueyi Xing et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

Expression of laminin subunit alpha 3 (LAMA3) in pancreatic ductal adenocarcinoma (PDAC) and normal tissues from the Cancer Genome Atlas (TCGA) database (A) and the Gene Expression Omnibus (GEO) database (B–E). Expression of LAMA3 in 179 PDAC and 332 normal tissues from TCGA (A); Expression of LAMA3 in 45 PDAC and 45 normal tissues from GSE28735 cohort (B); Expression of LAMA3 in 69 PDAC and 61 normal tissues from GSE62452 cohort (C); Expression of LAMA3 in 24 PDAC and 19 normal tissues from GSE101448 cohort (D); Expression of LAMA3 in 118 PDAC and 13 normal tissues from GSE62165 cohort (E).****P < 0.001.
Expression of laminin subunit alpha 3 (LAMA3) in pancreatic ductal adenocarcinoma (PDAC) and normal tissues from the Cancer Genome Atlas (TCGA) database (A) and the Gene Expression Omnibus (GEO) database (B–E). Expression of LAMA3 in 179 PDAC and 332 normal tissues from TCGA (A); Expression of LAMA3 in 45 PDAC and 45 normal tissues from GSE28735 cohort (B); Expression of LAMA3 in 69 PDAC and 61 normal tissues from GSE62452 cohort (C); Expression of LAMA3 in 24 PDAC and 19 normal tissues from GSE101448 cohort (D); Expression of LAMA3 in 118 PDAC and 13 normal tissues from GSE62165 cohort (E).****P < 0.001.

FIGURE 2.

The expression of laminin subunit alpha 3 (LAMA3) for prediction of overall survival (OS) and relapse free survival (RFS) in patients with pancreatic ductal adenocarcinoma (PDAC). OS (A), RFS (B).
The expression of laminin subunit alpha 3 (LAMA3) for prediction of overall survival (OS) and relapse free survival (RFS) in patients with pancreatic ductal adenocarcinoma (PDAC). OS (A), RFS (B).

FIGURE 3.

Representative immunohistochemical staining of laminin subunit alpha 3 (LAMA3) in pancreatic ductal adenocarcinoma (PDAC) and adjacent normal tissue. High expression of LAMA3 in PDAC tissue (A) compared with adjacent tissue (B). Low expression of LAMA3 in PDAC tissue (C) compared with adjacent tissue (D). Magnification, ×400
Representative immunohistochemical staining of laminin subunit alpha 3 (LAMA3) in pancreatic ductal adenocarcinoma (PDAC) and adjacent normal tissue. High expression of LAMA3 in PDAC tissue (A) compared with adjacent tissue (B). Low expression of LAMA3 in PDAC tissue (C) compared with adjacent tissue (D). Magnification, ×400

FIGURE 4.

Representative immunohistochemical staining of laminin subunit alpha 3 (LAMA3) in pancreatic ductal adenocarcinoma (PDAC) with and without liver metastasis. Low expression of LAMA3 in PDAC tissues (A) without liver metastatic. High expression of LAMA3 in PDAC tissues (B) with liver metastasis. Magnification, ×400.
Representative immunohistochemical staining of laminin subunit alpha 3 (LAMA3) in pancreatic ductal adenocarcinoma (PDAC) with and without liver metastasis. Low expression of LAMA3 in PDAC tissues (A) without liver metastatic. High expression of LAMA3 in PDAC tissues (B) with liver metastasis. Magnification, ×400.

FIGURE 5.

The expression of laminin subunit alpha 3 (LAMA3) for prediction of overall survival (OS) in patients with Pancreatic ductal adenocarcinoma (PDAC). Survival analysis was carried out with Kaplan-Meier and checked by log-rank test.
The expression of laminin subunit alpha 3 (LAMA3) for prediction of overall survival (OS) in patients with Pancreatic ductal adenocarcinoma (PDAC). Survival analysis was carried out with Kaplan-Meier and checked by log-rank test.

Univariate and multivariate Cox proportional hazard regression analyses of overall survival

Variables Univariate analysis Multivariate analysis
HR (95% CI) P-value HR 95% CI) P-value
Age 1.009 (0.985–1.035) 0.459 1.009 (0.983–1.035) 0.512
Sex 1.346 (0.850–2.131) 0.205 0.696 (0.435–1.112) 0.696
Tumor location (head vs. body and tail) 0.895 (0.573–1.399) 0.628 0.780 (0.474–1.283) 0.327
Tumor size
  ≤ 2 cm vs. > 4 cm 0.543 (0.186–1.583) 0.263 0.626 (0.191–2.054) 0.440
  > 2 cm and ≤ 4 cm vs. > 4 cm 0.607 (0.373–0.987) 0.044 0.637 (0.337–1.204) 0.165
Histological grade (G1 vs. G2–3) 1.263 (0.778–2.049) 0.345 1.378 (0.797–2.383) 0.251
TNM stage (I–II vs. III–IV) 0.374 (0.227–0.615) < 0.001 1.505 (0.855–2.647) 0.157
Perineural invasion (yes vs. no) 0.803 (0.464–1.389) 0.432 1.158 (0.611–2.196) 0.652
Vascular invasion (yes vs. no) 0.693 (0.442–1.085) 0.109 0.912 (0.529–1.572) 0.741
Lymph node metastasis (yes vs. no) 0.796 (0.513–1.235) 0.308 0.883 (0.548–1.423) 0.609
Liver metastasis (yes vs. no) 0.364 (0.231–0.574) < 0.001 2.284 (1.426–3.657) 0.001
CEA (≤12 vs. >12) 0.512 (0.256–1.026) 0.059 1.622 (0.788–3.340) 0.189
CA19-9(≤282 vs. >282) 0.969 (0.613–1.533) 0.894 0.963 (0.560–1.655) 0.891
LAMA3 (low vs. high) 0.407 (0.259–0.641) < 0.001 2.016 (1.257–3.234) 0.004

Characteristics of all patients

Characteristics All LAMA3 expression
High (n = 62) Low (n = 55) P- value
Age(year), mean±SD 62.43 ± 9.33 62.19 ± 9.38 62.69 ± 9.36 0.775
Sex, n (%) 0.615
  Male 73 (62.4) 40 33
  Female 64 (37.6) 22 22
Tumor location, n (%) 0.054
  Head 70 (59.8) 32 38
  Body and tail 47 (40.2) 30 17
Tumor size, n (%) 0.007
  ≤ 2 cm 5 (4.3) 2 3
  > 2 cm and ≤ 4 cm 81 (69.2) 37 44
  > 4 cm 31 (26.5) 23 8
Histological grade, n (%) 0.810
  G1 31 (26.5) 17 14
  G2–3 86 (73.5) 45 41
TNM stage, n (%) 0.002
  I–II 92 (78.6) 42 50
  III–IV 25 (21.4) 20 5
Perineural invasion, n (%) 0.921
  Yes 91 (77.8) 48 43
  No 26 (22.2) 14 12
Vascular invasion, n (%) 0.340
  Yes 37 (31.6) 22 15
  No 80 (68.4) 40 40
Lymph node metastasis, n (%) 0.255
  Yes 49 (41.9) 29 20
  No 68 (58.2) 33 35
Liver metastasis, n (%) 0.005
  Yes 45 30 15
  No 72 29 43
CEA (ng/ml) 0.392
  ≤ 12 108 (92.3) 56 52
  > 12 9 (7.7) 6 3
CA19-9 (U/ml) 0.395
  ≤ 282 74 (63.2) 37 37
  > 282 43 (36.8) 25 18
Surgical modalities, n (%) 0.036
  Pancreaticoduodenectomy 69 (59) 31 38
  Distal pancreatectomy 48 (41) 31 17
Postoperative chemotherapy, n (%) 0.77
  Yes 60 40 20
  No 57 41 16
Postoperative radiotherapy, n (%) 0.063
  Yes 3 2 1
  No 114 79 35
Immunotherapy, n (%) 0.068
  Yes 6 4 2
  No 111 77 34
Interventional therapy, n (%) 0.374
  Yes 4 4
  No 114 77 36

Univariate analysis of clinicopathological characteristics in patients with pancreatic ductal adenocarcinoma with and without liver metastasis

Characteristics Liver metastasis (n = 45) Without liver metastasis (n = 72) P-value
Age (year), M (IQR) 63 (58–69) 63 (56–68) 0.814
Sex, n 0.717
  Male 29 44
  Female 16 28
Tumor location, n 0.456
  Head 25 45
  Body and tail 20 27
Tumor size, n 0.240
  ≤ 2 cm 2 3
  > 2 cm and ≤4 cm 28 53
  > 4 cm 15 16
Histological grade, n 0.001
  G1 20 11
  G2–3 25 61
TNM stage, n 0.013
  I–II 30 62
  III–IV 15 10
Perineural invasion, n 0.170
  Yes 38 53
  No 7 19
Vascular invasion, n 0.018
  Yes 20 17
  No 25 55
Lymph node metastasis, n 0.110
  Yes 23 26
  No 22 46
CEA (ng/ml) 0.701
  ≤ 12 41 67
  > 12 4 5
CA19-9 (U/ml) 0.832
  ≤ 282 29 45
  > 282 16 27
LAMA3 expression, n 0.005
  High 30 29
  Low 15 43
eISSN:
1581-3207
Lingua:
Inglese
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Feed RSS della rivista